Liquidity and Capital Resources (Details) - USD ($)		1 Months Ended	3 Months Ended
	May 03, 2017	Apr. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Estimated Projected Expenditure [Line Items]
Cash and cash equivalents			$ 48,003,315	$ 68,162,754	$ 56,959,485	$ 22,261,372
Proceeds from exercise of warrants			0	$ 183,000
Currently projected expenditures for clinical programs			40,500,000
Milestone payment to licensor			1,500,000
Subsequent Event [Member]
Estimated Projected Expenditure [Line Items]
Proceeds from issuance common stock payment	$ 13,900,000
Proceeds from exercise of warrants		$ 1,900,000
Aldoxorubicin [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs			13,000,000
Other Programs [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs			3,600,000
General Operation [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs			4,700,000
Other General and Administrative Expenses [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs			8,700,000
Interest and Term Loan Payment [Member]
Estimated Projected Expenditure [Line Items]
Currently projected expenditures for clinical programs			$ 10,500,000